Clinical trial · Interventional
Skeletal Muscle Atrophy and Dysfunction in Human Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer and its treatment can have profound effects on skeletal muscle, the most well-recognized being atrophy, weakness and diminished oxidative capacity. These adaptations negatively impact quality of life, treatment decisions and survival. Despite these consequences, the factors promoting these adaptations remain poorly defined and understudied in human patients. To address this gap in knowledge, our goal in this study is to examine the role of muscle disuse as a regulator of muscle size and function in human cancer patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nonsmall Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exercise | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Exercise
- description
- Lung cancer patients will undergo unilateral resistance exercise 3 times per week for 8 weeks during cancer treatment, while the other leg remains unexercised and will serve as a within-subject control.
- interventionNames
- Behavioral: Exercise
Primary outcomes (4)
- measure
- Cross-sectional area of skeletal muscle fibers
- timeFrame
- Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks
- description
- Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types
- measure
- Single muscle fiber contractile function
- timeFrame
- Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 50-75 yrs of age * histologically-documented, stage III or IV non-small cell lung carcinoma (NSCLC) * estimated life expectancy \>6 mos * Karnofsky's performance score of ≥70 Exclusion Criteria: * history, signs or symptoms of inflammatory or autoimmune disease * uncontrolled hypertension * heart or renal failure * exercise limitations from peripheral vascular disease or stroke * neuromuscular disease * knee/hip replacement * additional, actively-treated malignancy or history of malignancy, except non-melanoma skin cancer * taking medication that can have anti-coagulant effects that cannot be stopped prior to the muscle biopsy
References
Publications (0)
Data not yet available